31
Participants
Start Date
October 12, 2020
Primary Completion Date
October 5, 2023
Study Completion Date
November 30, 2026
Fedratinib
Specified dose on specified days
Local Institution - 009, Nagasaki
Local Institution - 020, Kumamoto
Local Institution - 021, Suwa
Local Institution - 001, Bunkyo-ku
Local Institution - 006, Chūō
Local Institution - 002, Aomori
Local Institution - 004, Bunkyō City
Local Institution - 015, Fukuoka
Local Institution - 018, Hitachi, Ibaraki
Local Institution - 005, Isehara City, Kanagawa
Local Institution - 010, Kamogawa
Local Institution - 017, Kitakyushu
Local Institution - 013, Maebashi
Local Institution - 012, Miyazaki
Local Institution - 016, Osaka
Local Institution - 011, Ōsaka-sayama
Local Institution - 014, Sapporo
Local Institution - 007, Shinagawa-ku, Tokyo
Local Institution - 008, Shinjuku
Local Institution - 003, Shinjyuku-ku
Local Institution - 019, Takamatsu
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY